Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1996 1
1998 1
1999 1
2001 1
2003 4
2004 2
2005 4
2006 1
2007 2
2008 1
2009 4
2010 2
2011 6
2012 7
2013 5
2014 9
2015 9
2016 4
2017 4
2018 9
2019 6
2020 5
2021 4
2022 3
2023 7
2024 5
2025 6

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

98 results

Results by year

Filters applied: . Clear all
Page 1
Allogeneic Hematopoietic Cell Transplantation vs Standard Consolidation Chemotherapy in Patients With Intermediate-Risk Acute Myeloid Leukemia: A Randomized Clinical Trial.
Bornhäuser M, Schliemann C, Schetelig J, Röllig C, Kramer M, Glass B, Platzbecker U, Burchert A, Hänel M, Müller LP, Klein S, Bug G, Beelen D, Rösler W, Schäfer-Eckart K, Schmid C, Jost E, Lenz G, Tischer J, Spiekermann K, Pfirrmann M, Serve H, Stölzel F, Alakel N, Middeke JM, Thiede C, Ehninger G, Berdel WE, Stelljes M. Bornhäuser M, et al. Among authors: pfirrmann m. JAMA Oncol. 2023 Apr 1;9(4):519-526. doi: 10.1001/jamaoncol.2022.7605. JAMA Oncol. 2023. PMID: 36757706 Free PMC article. Clinical Trial.
Prognostic scoring systems in chronic myeloid leukaemia.
Lauseker M, Hoffmann VS, Pfirrmann M. Lauseker M, et al. Among authors: pfirrmann m. Leukemia. 2025 May;39(5):1046-1052. doi: 10.1038/s41375-025-02606-6. Epub 2025 Apr 15. Leukemia. 2025. PMID: 40234613 Free PMC article. Review.
Management and outcome of patients with chronic myeloid leukemia in blast phase in the tyrosine kinase inhibitor era - analysis of the European LeukemiaNet Blast Phase Registry.
Brioli A, Lomaia E, Fabisch C, Sacha T, Klamova H, Morozova E, Golos A, Ernst P, Olsson-Stromberg U, Zackova D, Nicolini FE, Bao H, Castagnetti F, Patkowska E, Mayer J, Hirschbühl K, Podgornik H, Paczkowska E, Parry A, Ernst T, Voskanyan A, Szczepanek E, Saussele S, Franke GN, Kiani A, Faber E, Krause S, Casado LF, Lewandowski K, Eder M, Anhut P, Gil J, Südhoff T, Hebart H, Heibl S, Pfirrmann M, Hochhaus A, Lauseker M. Brioli A, et al. Among authors: pfirrmann m. Leukemia. 2024 May;38(5):1072-1080. doi: 10.1038/s41375-024-02204-y. Epub 2024 Mar 28. Leukemia. 2024. PMID: 38548962 Free PMC article.
Health-related quality of life and symptoms of chronic myeloid leukemia patients after discontinuation of tyrosine kinase inhibitors: results from the EURO-SKI Trial.
Efficace F, Mahon FX, Richter J, Piciocchi A, Cipriani M, Nicolini FE, Mayer J, Zackova D, Janssen JJWM, Panayiotidis P, Vestergaard H, Koskenvesa P, Almeida A, Hjorth-Hansen H, Martinez-Lopez J, Olsson-Strömberg U, Hochhaus A, Berger MG, Etienne G, Klamova H, Faber E, Rousselot P, Pfirrmann M, Saussele S. Efficace F, et al. Among authors: pfirrmann m. Leukemia. 2024 Aug;38(8):1722-1730. doi: 10.1038/s41375-024-02341-4. Epub 2024 Jul 10. Leukemia. 2024. PMID: 38987274
Clinical trials in chronic myeloid leukemia.
Saussele S, Pfirrmann M. Saussele S, et al. Among authors: pfirrmann m. Curr Hematol Malig Rep. 2012 Jun;7(2):109-15. doi: 10.1007/s11899-012-0118-1. Curr Hematol Malig Rep. 2012. PMID: 22422549 Review.
A surgically optimized intraoperative poly(I:C)-releasing hydrogel prevents cancer recurrence.
Rwandamuriye FX, Evans CW, Wylie B, Norret M, Vitali B, Ho D, Nguyen D, Roper EA, Wang T, Hepburn MS, Sanderson RW, Pfirrmann M, Fear VS, Forbes CA, Wyatt K, Ryan AL, Johns TG, Phillips MB, Hodder R, Leslie C, Kennedy BF, Zemek RM, Iyer KS, Lesterhuis WJ. Rwandamuriye FX, et al. Among authors: pfirrmann m. Cell Rep Med. 2023 Jul 18;4(7):101113. doi: 10.1016/j.xcrm.2023.101113. Cell Rep Med. 2023. PMID: 37467718 Free PMC article.
European Stop Tyrosine Kinase Inhibitor Trial (EURO-SKI) in Chronic Myeloid Leukemia: Final Analysis and Novel Prognostic Factors for Treatment-Free Remission.
Mahon FX, Pfirrmann M, Dulucq S, Hochhaus A, Panayiotidis P, Almeida A, Mayer J, Hjorth-Hansen H, Janssen JJWM, Mustjoki S, Martinez-Lopez J, Vestergaard H, Ehrencrona H, Machová Poláková K, Olsson-Strömberg U, Ossenkoppele G, Berger MG, Etienne G, Dengler J, Brümmendorf TH, Burchert A, Réa D, Rousselot P, Nicolini FE, Hofmann WK, Richter J, Saussele S; EURO-SKI Investigators; Investigators. Mahon FX, et al. Among authors: pfirrmann m. J Clin Oncol. 2024 Jun 1;42(16):1875-1880. doi: 10.1200/JCO.23.01647. Epub 2024 Mar 12. J Clin Oncol. 2024. PMID: 38471049
The JAK1/2 inhibitor ruxolitinib in patients with COVID-19 triggered hyperinflammation: the RuxCoFlam trial.
Hammersen J, Birndt S, Döhner K, Reuken P, Stallmach A, Sauerbrey P, La Rosée F, Pfirrmann M, Fabisch C, Weiss M, Träger K, Bremer H, Russo S, Illerhaus G, Drömann D, Schneider S, La Rosée P, Hochhaus A. Hammersen J, et al. Among authors: pfirrmann m. Leukemia. 2023 Sep;37(9):1879-1886. doi: 10.1038/s41375-023-01979-w. Epub 2023 Jul 28. Leukemia. 2023. PMID: 37507425 Free PMC article.
98 results